Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Scrip's Rough Guide To CRISPR Gene Editing

Executive Summary

CRISPR technology was invented less than four years ago but is so accurate, versatile, easy to use, and inexpensive that it has spread quickly through biology laboratories, transforming the way gene editing is done and offering its potential use in a wide array of therapies. Here Scrip tells you all you need to know about this disruptive technology.

Advertisement

Related Content

Exonics Using CRISPR To Develop One-Time Treatment for Duchenne
IPO Update: Values Slip As Four More Biopharma Firms Go Public In October
IPO Update: Novan, AC Immune End Summer Slowdown As Market Improves
China Surprises With First CRISPR Trial Despite Regulatory Lag, Concerns
Head of Bayer LifeScience Center: Expect More JVs

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC065465

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel